PMID- 20307595
OWN - NLM
STAT- MEDLINE
DCOM- 20100728
LR  - 20211020
IS  - 1873-2518 (Electronic)
IS  - 0264-410X (Print)
IS  - 0264-410X (Linking)
VI  - 28
IP  - 22
DP  - 2010 May 14
TI  - Comparison of egg and high yielding MDCK cell-derived live attenuated influenza 
      virus for commercial production of trivalent influenza vaccine: in vitro cell 
      susceptibility and influenza virus replication kinetics in permissive and 
      semi-permissive cells.
PG  - 3848-55
LID - 10.1016/j.vaccine.2010.03.005 [doi]
AB  - Currently MedImmune manufactures cold-adapted (ca) live, attenuated influenza 
      vaccine (LAIV) from specific-pathogen free (SPF) chicken eggs. Difficulties in 
      production scale-up and potential exposure of chicken flocks to avian influenza 
      viruses especially in the event of a pandemic influenza outbreak have prompted 
      evaluation and development of alternative non-egg based influenza vaccine 
      manufacturing technologies. As part of MedImmune's effort to develop the live 
      attenuated influenza vaccine (LAIV) using cell culture production technologies we 
      have investigated the use of high yielding, cloned MDCK cells as a substrate for 
      vaccine production by assessing host range and virus replication of influenza 
      virus produced from both SPF egg and MDCK cell production technologies. In 
      addition to cloned MDCK cells the indicator cell lines used to evaluate the 
      impact of producing LAIV in cells on host range and replication included two 
      human cell lines: human lung carcinoma (A549) cells and human muco-epidermoid 
      bronchiolar carcinoma (NCI H292) cells. The influenza viruses used to infect the 
      indicators cell lines represented both the egg and cell culture manufacturing 
      processes and included virus strains that composed the 2006-2007 influenza 
      seasonal trivalent vaccine (A/New Caledonia/20/99 (H1N1), A/Wisconsin/67/05 
      (H3N2) and B/Malaysia/2506/04). Results from this study demonstrate remarkable 
      similarity between influenza viruses representing the current commercial egg 
      produced and developmental MDCK cell produced vaccine production platforms. 
      MedImmune's high yielding cloned MDCK cells used for the cell culture based 
      vaccine production were highly permissive to both egg and cell produced ca 
      attenuated influenza viruses. Both the A549 and NCI H292 cells regardless of 
      production system were less permissive to influenza A and B viruses than the MDCK 
      cells. Irrespective of the indicator cell line used the replication properties 
      were similar between egg and the cell produced influenza viruses. Based on these 
      study results we conclude that the MDCK cell produced and egg produced vaccine 
      strains are highly comparable.
CI  - Copyright 2010 Elsevier Ltd. All rights reserved.
FAU - Hussain, Althaf I
AU  - Hussain AI
AD  - Cell Culture Process Development, MedImmune, LLC 3055 Patrick Henry Dr., Santa 
      Clara, CA 95054, USA. hussaina@medimmune.com
FAU - Cordeiro, Melissa
AU  - Cordeiro M
FAU - Sevilla, Elizabeth
AU  - Sevilla E
FAU - Liu, Jonathan
AU  - Liu J
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100320
PL  - Netherlands
TA  - Vaccine
JT  - Vaccine
JID - 8406899
RN  - 0 (Influenza Vaccines)
RN  - 0 (RNA, Viral)
RN  - 0 (Vaccines, Attenuated)
SB  - IM
MH  - Animals
MH  - Cell Line, Tumor
MH  - Chickens
MH  - Dogs
MH  - Eggs/virology
MH  - Hemagglutination Inhibition Tests
MH  - Humans
MH  - Influenza A Virus, H1N1 Subtype/*growth & development/immunology/physiology
MH  - Influenza A Virus, H3N2 Subtype/*growth & development/immunology/physiology
MH  - Influenza Vaccines/*biosynthesis/immunology
MH  - RNA, Viral/analysis
MH  - Vaccines, Attenuated/biosynthesis/immunology
MH  - *Virus Replication
PMC - PMC7172923
EDAT- 2010/03/24 06:00
MHDA- 2010/07/29 06:00
PMCR- 2010/03/20
CRDT- 2010/03/24 06:00
PHST- 2009/10/01 00:00 [received]
PHST- 2010/02/21 00:00 [revised]
PHST- 2010/03/05 00:00 [accepted]
PHST- 2010/03/24 06:00 [entrez]
PHST- 2010/03/24 06:00 [pubmed]
PHST- 2010/07/29 06:00 [medline]
PHST- 2010/03/20 00:00 [pmc-release]
AID - S0264-410X(10)00341-5 [pii]
AID - 10.1016/j.vaccine.2010.03.005 [doi]
PST - ppublish
SO  - Vaccine. 2010 May 14;28(22):3848-55. doi: 10.1016/j.vaccine.2010.03.005. Epub 
      2010 Mar 20.